Financial report

Interim consolidated income statement

For the six months ended 30 June 2021 (unaudited)

 

 

 

 

kEUR

Note

H1 2021

H1 2020

 

 

 

 

Revenue

4

135,136

87,808

Other operating income

 

2,936

619

Total income

 

138,072

88,427

 

 

 

 

Cost of sales

 

-86,839

-64,327

Gross profit

 

51,233

24,100

 

 

 

 

Marketing and sales expenses

 

-2,133

-1,791

Research expenses

 

-696

-599

General and administrative expenses

 

-17,601

-11,550

Total operating expenses

 

-20,430

-13,940

 

 

 

 

Operating result

 

30,803

10,160

Financial income

 

6

44

Financial expenses

 

-1,282

-904

Total financial result

 

-1,276

-860

 

 

 

 

Result before income taxes

 

29,527

9,300

Income tax charges

 

-4,904

-1,469

 

 

 

 

Result for the period

 

24,623

7,831

Attributable to shareholders of PolyPeptide Group AG

 

24,623

7,831

 

 

 

 

Result for the period

 

24,623

7,831

 

 

 

 

Earnings per share in EUR, basic

 

0.79

0.26

Earnings per share in EUR, diluted

 

0.79

0.26